9 METERS BIOPHARMA, INC.

2021 Q1 Form 10-Q Financial Statement

#000155198621000065 Filed on May 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $38.50M $2.670M
YoY Change 1341.95% -76.76%
Cash & Equivalents $38.50M $2.668M
Short-Term Investments
Other Short-Term Assets $1.490M $570.0K
YoY Change 161.4% -41.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $39.98M $3.231M
YoY Change 1137.53% -74.1%
LONG-TERM ASSETS
Property, Plant & Equipment $15.09K $20.14K
YoY Change -25.05% -32.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.580K $5.580K
YoY Change 0.0% 0.0%
Total Long-Term Assets $223.9K $54.70K
YoY Change 309.44% -53.46%
TOTAL ASSETS
Total Short-Term Assets $39.98M $3.231M
Total Long-Term Assets $223.9K $54.70K
Total Assets $40.21M $3.286M
YoY Change 1123.74% -73.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.371M $5.075M
YoY Change -72.99% 29.19%
Accrued Expenses $4.566M $4.848M
YoY Change -5.81% 440.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $4.300M
YoY Change -100.0% 14.97%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.987M $15.84M
YoY Change -62.19% 44.7%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $150.0K
YoY Change
Total Long-Term Liabilities $150.0K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.987M $15.84M
Total Long-Term Liabilities $150.0K $0.00
Total Liabilities $6.142M $15.84M
YoY Change -61.23% 44.36%
SHAREHOLDERS EQUITY
Retained Earnings -$137.5M -$74.17M
YoY Change 85.38% 54.67%
Common Stock $21.63K $4.133K
YoY Change 423.4% 33.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $34.07M -$12.55M
YoY Change
Total Liabilities & Shareholders Equity $40.21M $3.286M
YoY Change 1123.74% -73.9%

Cashflow Statement

Concept 2021 Q1 2020 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001551986
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-37797
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
9 METERS BIOPHARMA, INC.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3948465
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
8480 Honeycutt Road
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 120
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Raleigh
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27615
CY2021Q1 dei City Area Code
CityAreaCode
919
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
275-1933
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock $0.0001 Par Value
CY2021Q1 dei Trading Symbol
TradingSymbol
NMTR
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
251372296 shares
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38496108 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37851388 USD
CY2021Q1 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
75000 USD
CY2020Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
75000 USD
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1412862 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1000587 USD
CY2021Q1 us-gaap Assets Current
AssetsCurrent
39983970 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
38926975 USD
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15093 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11191 USD
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
203269 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
214767 USD
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5580 USD
CY2021Q1 us-gaap Assets
Assets
40207912 USD
CY2020Q4 us-gaap Assets
Assets
39158513 USD
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1370679 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1487948 USD
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4566320 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5290181 USD
CY2021Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 USD
CY2020Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
14216 USD
CY2021Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 USD
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
7000 USD
CY2021Q1 us-gaap Interest Payable Current
InterestPayableCurrent
0 USD
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
488 USD
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
50102 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
48629 USD
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5987101 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6848462 USD
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
154846 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
167938 USD
CY2021Q1 us-gaap Liabilities
Liabilities
6141947 USD
CY2020Q4 us-gaap Liabilities
Liabilities
7016400 USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
216324896 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
216324896 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
204629064 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
204629064 shares
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
21632 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
20463 USD
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
171536679 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
164182917 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-137492346 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-132061267 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
34065965 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
32142113 USD
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40207912 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39158513 USD
CY2021Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3190302 USD
CY2020Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2598985 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2208800 USD
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1669807 USD
CY2021Q1 nmtr Warrant Inducement Expense
WarrantInducementExpense
0 USD
CY2020Q1 nmtr Warrant Inducement Expense
WarrantInducementExpense
690839 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
5399102 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
4959631 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5399102 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4959631 USD
CY2021Q1 us-gaap Interest Income Other
InterestIncomeOther
5087 USD
CY2020Q1 us-gaap Interest Income Other
InterestIncomeOther
12815 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
44064 USD
CY2020Q1 us-gaap Interest Expense
InterestExpense
572985 USD
CY2021Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
7000 USD
CY2020Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
338000 USD
CY2021Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1578800 USD
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-31977 USD
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1356630 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5431079 USD
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3603001 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5431079 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3603001 USD
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
211280867 shares
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41162296 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
32142113 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
422000 USD
CY2021Q1 nmtr Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
6857028 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
75903 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5431079 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
34065965 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-9614014 USD
CY2020Q1 nmtr Stock Issued During Period Value Warrant Exchange
StockIssuedDuringPeriodValueWarrantExchange
690839 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
276000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
300000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3603001 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-12550176 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5431079 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3603001 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
422000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
276000 USD
CY2021Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
0 USD
CY2020Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
81972 USD
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
43983 USD
CY2021Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-488 USD
CY2020Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
481024 USD
CY2021Q1 us-gaap Depreciation
Depreciation
1110 USD
CY2020Q1 us-gaap Depreciation
Depreciation
5284 USD
CY2021Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-7000 USD
CY2020Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-338000 USD
CY2021Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1578800 USD
CY2021Q1 nmtr Warrant Inducement Expense
WarrantInducementExpense
0 USD
CY2020Q1 nmtr Warrant Inducement Expense
WarrantInducementExpense
690839 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
269942 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-66841 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-117269 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1185384 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-866315 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
100072 USD
CY2020Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6225000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2632385 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5012 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5012 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2021Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
CY2020Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2500000 USD
CY2021Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
58199 USD
CY2020Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
1469804 USD
CY2021Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
CY2020Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
23000 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
75903 USD
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2020Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
300000 USD
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6857028 USD
CY2020Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6874732 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
707196 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
644720 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1925189 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37851388 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4592932 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38496108 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2667743 USD
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
569 USD
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
54578 USD
CY2021Q1 nmtr Noncash Addition Of Derivative Liability
NoncashAdditionOfDerivativeLiability
0 USD
CY2020Q1 nmtr Noncash Addition Of Derivative Liability
NoncashAdditionOfDerivativeLiability
370000 USD
CY2021Q1 nmtr Noncash Addition Of Deferred Offering Costs
NoncashAdditionOfDeferredOfferingCosts
142333 USD
CY2020Q1 nmtr Noncash Addition Of Deferred Offering Costs
NoncashAdditionOfDeferredOfferingCosts
0 USD
CY2020Q4 nmtr Saleof Stock Shelf Registration Maximum Equity Offering Price
SaleofStockShelfRegistrationMaximumEquityOfferingPrice
200000000 USD
CY2019Q4 nmtr Class Of Warrant Or Right Number Of Shares Issued Per Warrant
ClassOfWarrantOrRightNumberOfSharesIssuedPerWarrant
1.2 shares
CY2020Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
12230418 shares
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.10
CY2020Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1200000 USD
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.10
CY2020Q2 us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
22600000 USD
CY2020Q2 nmtr Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants Net
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrantsNet
19200000 USD
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4566320 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5290181 USD
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Areas of the financial statements where estimates may have the most significant effect include accrued expenses, share-based compensation, valuation of the derivative liability and warrant liabilities, valuation allowance for income tax assets, and management’s assessment of the Company’s ability to continue as a going concern. The Company considered the impact of the COVID-19 pandemic on its estimates and assumptions, and concluded there was not a material impact to its condensed consolidated financial statements as of and for the three months ended March 31, 2021. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates.</span></div>
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
697376 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1111028 USD
CY2021Q1 nmtr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
3764663 USD
CY2020Q4 nmtr Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
4042277 USD
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
104281 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
136876 USD
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
47700000 shares
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21200000 shares
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
7000 USD
CY2021Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0 USD
CY2021Q1 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
0 USD
CY2021Q1 nmtr Warrants Accumulated Gross Unrealized Gain
WarrantsAccumulatedGrossUnrealizedGain
7000 USD
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1600000 USD
CY2021Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
47681586 shares
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21247679 shares
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38500000 USD
CY2020Q2 nmtr Number Of Amended And Restated License Agreements
NumberOfAmendedAndRestatedLicenseAgreements
2 license_agreement
CY2021Q1 nmtr Accrued Milestone Fees
AccruedMilestoneFees
0 USD
CY2020Q1 nmtr Accrued Milestone Fees
AccruedMilestoneFees
0 USD
CY2020Q3 nmtr Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
6000 USD
CY2020Q3 nmtr Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
6000 USD
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2021Q1 nmtr Capital Stock Authorized
CapitalStockAuthorized
360000000 shares
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
600000 shares
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 nmtr Convertible Preferred Stock Beneficial Conversion Feature
ConvertiblePreferredStockBeneficialConversionFeature
3100000 USD
CY2020Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
12500000 USD
CY2020Q2 nmtr Preferred Stock Warrant Value
PreferredStockWarrantValue
7000000.0 USD
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
216324896 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
204629064 shares
CY2021Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
54447630 shares
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
66167171 shares
CY2021Q1 nmtr Number Of Stock Option Plans
NumberOfStockOptionPlans
2 plan
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
422000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
276000 USD
CY2021Q1 nmtr Severance Provisions Annual Base Salary Period
SeveranceProvisionsAnnualBaseSalaryPeriod
P12M
CY2021Q1 nmtr Severance Provisions Continuation Of Health Insurance Benefits Period
SeveranceProvisionsContinuationOfHealthInsuranceBenefitsPeriod
P12M
CY2020Q1 us-gaap Severance Costs1
SeveranceCosts1
0 USD
CY2021Q1 us-gaap Severance Costs1
SeveranceCosts1
0 USD
CY2021Q1 nmtr Accrued Severance Costs
AccruedSeveranceCosts
100000 USD
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2020Q3 nmtr Operating Lease Annual Rental Payments
OperatingLeaseAnnualRentalPayments
72000 USD
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
18000 USD
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
233206 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
233206 USD
CY2017Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
15000 USD
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
100000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
54000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
72000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
72000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
54000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
252000 USD
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
47052 USD
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
204948 USD

Files In Submission

Name View Source Status
0001551986-21-000065-index-headers.html Edgar Link pending
0001551986-21-000065-index.html Edgar Link pending
0001551986-21-000065.txt Edgar Link pending
0001551986-21-000065-xbrl.zip Edgar Link pending
ex311q12021.htm Edgar Link pending
ex312q12021.htm Edgar Link pending
ex321q12021.htm Edgar Link pending
ex322q12021.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nmtr-20210331.htm Edgar Link pending
nmtr-20210331.xsd Edgar Link pending
nmtr-20210331_cal.xml Edgar Link unprocessable
nmtr-20210331_def.xml Edgar Link unprocessable
nmtr-20210331_g1.jpg Edgar Link pending
nmtr-20210331_htm.xml Edgar Link completed
nmtr-20210331_lab.xml Edgar Link unprocessable
nmtr-20210331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending